LGND Share Price

Open 121.70 Change Price %
High 123.13 1 Day 2.36 1.96
Low 120.11 1 Week 4.40 3.71
Close 123.05 1 Month -0.08 -0.06
Volume 220092 1 Year -9.50 -7.17
52 Week High 139.79
52 Week Low 87.50
LGND Important Levels
Resistance 2 125.85
Resistance 1 124.70
Pivot 122.10
Support 1 121.40
Support 2 120.25
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ASTI 0.00 0.00%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
TEAR 3.34 89.77%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TOPS 0.26 23.81%
BONT 0.80 17.65%
HAUP 0.07 16.67%
PLUG 2.44 15.09%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

LGND Technical Analysis 5
As on 21st Jul 2017 LGND Share Price closed @ 123.05 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 107.43 & Strong Buy for SHORT-TERM with Stoploss of 115.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
LGND Target for July
1st Target up-side 130.55
2nd Target up-side 136.96
3rd Target up-side 143.37
1st Target down-side 112.25
2nd Target down-side 105.84
3rd Target down-side 99.43
LGND Other Details
Segment EQ
Market Capital 357465760.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ligand.com
LGND Address
LGND
11119 North Torrey Pines Road
Suite 200
La Jolla, CA 92037
United States
Phone: 858-550-7500
LGND Latest News
Interactive Technical Analysis Chart Ligand Pharmaceuticals Incorporated ( LGND NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ligand Pharmaceuticals Incorporated
LGND Business Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company�s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer�s VFEND IV and Baxter International�s Nexterone and is being used in a number of clinical-stage partner programs. The therapies in its portfolio in development address the unmet medical needs of patients for a spectrum of diseases, including hepatitis, muscle wasting, Alzheimer�s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. It�s wholly owned subsidiaries include Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., Pharmacopeia, LLC, Neurogen Corporation, CyDex Pharmaceuticals, Inc. and Metabasis Therapeutics. On January 26, 2011, the Company acquired CyDex Pharmaceuticals, Inc. (CyDex).